Have No (Or Very Little) Fear In The Face Of Record High Stock Prices

“Owning stocks at all-time highs can feel like standing at the top of a skyscraper and looking over the edge. After all…stock prices are higher than they’ve ever been. That can only mean danger. Right?” asks the author of today’s article. His answer – and what 100 years’ worth of data shows – is that, although record high stock prices may feel dangerous, they are as close to a “sure-thing” indicator to buy as investors can get. For more, CLICK HERE.

This “Invisible” Company Is Powering Direct Online Selling – And Could Double By 2022

“More and more companies are dumping not only retail stores but also Amazon to sell their products online. And there’s an invisible tech giant driving this trend,” states today’s article, which further notes that one in three Americans are buying through this company without even realizing it, making it second only to Amazon when it comes to being the biggest player in the online shopping space. Even more importantly, this company could see its sales double by 2022. For this disruptive stock to keep an eye on, CLICK HERE.

Generate Income From Debt With This Fund

If income is what you’re after in this low-interest-rate environment, and you prefer to avoid the risk associated with stocks, one alternative source of income worth considering is debt. Bank debt, to be more specific. Today’s article highlights a fund that buys subordinate debt of community banks and which “provides monthly income, lower volatility and the prospect of some capital gains.” For more on this niche fund, CLICK HERE.

“The Most Blatant Warning” For The Stock Market That’s Being Overlooked

From the yield curve inversion (which has preceded every recession since the end of World War II) to the very high – and rising – levels of corporate debt and more, there are a number of warning signs flashing for the stock market. However, the author of today’s article suggests that “The most blatant warning that the stock market may be on the verge of a problem” is one that Wall Street is overlooking – and it has to do with the surprising nature of some of this year’s outperformers . For more, CLICK HERE.

“Similar But Not The Same”: How To Maintain Upside Exposure While Taking Advantage Of Year-End Tax Loss Selling

“While it should never be the driver of investment decisions one needs to always keep an eye on tax implications as they can have a significant impact on the final total returns”, notes the author of today’s article. So with the end of the year fast approaching, how can investors take advantage of the benefits of tax loss selling while also working around the restrictions of the “wash sale rule” that prohibits the purchase of a “substantially identical” stock within 30 days of a sale? For some strategies, CLICK HERE.

The Right Sector Right Now – And A Safe 6.9% Dividend

While earnings are declining, the author of today’s article points out an important fact about the decline: it’s being largely driven by companies that rely on foreign markets for the majority of their sales, while earnings of companies that generate the majority of their sales domestically are actually rising. As a result, he argues, “the overall earnings decline isn’t a sign of a recession—and it isn’t reason to sell out of stocks…In fact, now is a great time to buy—so long as you do so selectively.” He proceeds to highlight one particular sector that may be a wise selection right now – and a specific fund paying a safe 6.9% dividend. For more, CLICK HERE.

2 Biotechs For Exposure To “Unique, Cutting-Edge” Approaches To Treating Alzheimer’s Disease

It has been over 15 years since any new drug for the treatment of Alzheimer’s has been approved – but a pair of relatively new biotechs focused on neurodegenerative diseases may be in the early stages of developing novel approaches to treat the disease, which currently afflicts 5.7 million Americans (and counting). For these two biotechs, which today’s article highlights as providing “investors with two avenues to get in on unique, cutting-edge research in Alzheimer’s disease”, CLICK HERE.

A Lesson In Late Cycle Investing

“The common perception is that over the past two years the broader stock market has surged upwards, with some indices making new record highs,” notes the author of today’s article. But he questions how true that perception is – and whether there have actually been better and safer alternatives for investors during this period late in the cycle. For this lesson on late cycle investing – including what investment has been the best performer by far since the beginning of 2018 – CLICK HERE.

As Trump Throws Cold Water On Trade Deal Hopes, Here Are 3 Stocks With Trade War Immunity

Just when it looked (once again) like the U.S.-China trade war could be cooling, President Trump declared that the U.S. has not yet agreed to roll back tariffs as part of a phase one trade deal. So while the bad news is that negotiations towards a trade deal with China (and end of the trade war) may still have a ways to go, the author of today’s article notes “the good news is there are money-making stocks outside the influence of the trade war available to investors who are willing to do a little digging” – and she proceeds to highlight three such stocks to consider. For more, CLICK HERE.